EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality

Anna Khalizieva, Sarah C Moser, Peter Bouwman, Jos Jonkers

Genes & Development · 2024

DOI: 10.1101/gad.352083.124 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes & Development, 2024. Verfasst von Anna Khalizieva und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: BRCA2 Protein, Synthetic Lethal Mutations, BRCA1 Protein, Genetic Predisposition to Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Oncode Institute, Dutch Cancer Society, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of BRCA1 and BRCA2 as tumor susceptibility genes and their role in genome maintenance has transformed our understanding of hereditary breast and ovarian cancer. This review traces the evolution of BRCA1/2 research over the past 30 years, highlighting key discoveries in the field and their contributions to tumor development. Additionally, we discuss current preventive measures for BRCA1/2 mutation carriers and targeted treatment options based on the concept of synthetic lethality. Finally, we explore the challenges of acquired therapy resistance and discuss potential alternative avenues for targeting BRCA1/2 mutant tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA2 ProteinSynthetic Lethal MutationsBRCA1 ProteinGenetic Predisposition to DiseaseHumansOvarian NeoplasmsBreast NeoplasmsFemaleAnimalsMutation

Stichwörter der Autor:innen

BRCA1BRCA2breast cancerhomologous recombinationsynthetic lethalitytumor suppressor

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA1 protein, humanBRCA2 protein, human

Autor:innen und Institutionen

  • Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • Oncode Institute, 3521 AL Utrecht, The Netherlands.
  • Division of Cell Systems and Drug Safety, Leiden Academic Center for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.
  • Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; j.jonkers@nki.nl s.moser@nki.nl r.j.p.bouwman@lacdr.leidenuniv.nl.
  • Division of Cell Systems and Drug Safety, Leiden Academic Center for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands j.jonkers@nki.nl s.moser@nki.nl r.j.p.bouwman@lacdr.leidenuniv.nl.

Förderung

  • Oncode Institute
  • Dutch Cancer Society
  • Swiss National Science Foundation
  • European Partnership for the Assessment of Risks from Chemicals
  • Horizon Europe Research and Innovation Programme
  • Horizon Europe 2021 Cancer Mission DISCERN
  • Boehringer Ingelheim Fonds

Zitieren

APA

Khalizieva, A., Moser, S. C., Bouwman, P., & Jonkers, J. (2024). BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality. Genes & Development. https://doi.org/10.1101/gad.352083.124

Vancouver

Khalizieva A, Moser SC, Bouwman P, Jonkers J. BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality. Genes & Development. 2024. doi:10.1101/gad.352083.124

BibTeX
@article{Khalizieva2024,
  author = {Khalizieva, Anna and Moser, Sarah C and Bouwman, Peter and Jonkers, Jos},
  title = {BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality},
  journal = {Genes & Development},
  year = {2024},
  doi = {10.1101/gad.352083.124}
}
Kostenlos starten →